La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
KPC PharmaceuticalsInc Croissance future
Future contrôle des critères 3/6
KPC PharmaceuticalsInc is forecast to grow earnings and revenue by 27.1% and 13.3% per annum respectively. EPS is expected to grow by 26.8% per annum. Return on equity is forecast to be 12.3% in 3 years.
Informations clés
27.1%
Taux de croissance des bénéfices
26.8%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 18.8% |
Taux de croissance des recettes | 13.3% |
Rendement futur des capitaux propres | 12.3% |
Couverture par les analystes | Good |
Dernière mise à jour | 13 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20
Jul 25Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)
Jun 25We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt
Jun 04KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues
Mar 28Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 11,008 | 949 | 168 | 1,021 | 6 |
12/31/2025 | 9,924 | 779 | 279 | 790 | 7 |
12/31/2024 | 8,563 | 597 | -33 | 720 | 6 |
3/31/2024 | 7,646 | 432 | 752 | 811 | N/A |
12/31/2023 | 7,703 | 445 | 291 | 356 | N/A |
9/30/2023 | 7,700 | 397 | 261 | 333 | N/A |
6/30/2023 | 7,825 | 390 | 141 | 222 | N/A |
3/31/2023 | 7,828 | 400 | -51 | 38 | N/A |
12/31/2022 | 8,282 | 383 | 152 | 254 | N/A |
9/30/2022 | 8,419 | 446 | 177 | 296 | N/A |
6/30/2022 | 8,388 | 392 | -23 | 143 | N/A |
3/31/2022 | 8,722 | 427 | -33 | 177 | N/A |
12/31/2021 | 8,254 | 508 | 15 | 252 | N/A |
9/30/2021 | 8,321 | 540 | -136 | 93 | N/A |
6/30/2021 | 8,386 | 564 | -22 | 190 | N/A |
3/31/2021 | 8,045 | 560 | -79 | 118 | N/A |
1/1/2021 | 7,717 | 457 | 251 | 410 | N/A |
9/30/2020 | 7,779 | 445 | 128 | 361 | N/A |
6/30/2020 | 7,788 | 444 | 104 | 393 | N/A |
3/31/2020 | 7,910 | 443 | 292 | 564 | N/A |
12/31/2019 | 8,120 | 454 | 82 | 430 | N/A |
9/30/2019 | 7,817 | 429 | 145 | 452 | N/A |
6/30/2019 | 7,473 | 390 | 131 | 376 | N/A |
3/31/2019 | 7,237 | 356 | 146 | 402 | N/A |
12/31/2018 | 7,102 | 336 | 135 | 352 | N/A |
9/30/2018 | 6,797 | 316 | 362 | 568 | N/A |
6/30/2018 | 6,507 | 295 | 162 | 396 | N/A |
3/31/2018 | 6,280 | 318 | -69 | 197 | N/A |
12/31/2017 | 5,852 | 330 | N/A | 283 | N/A |
9/30/2017 | 5,637 | 357 | N/A | -5 | N/A |
6/30/2017 | 5,330 | 374 | N/A | 165 | N/A |
3/31/2017 | 5,170 | 416 | N/A | 179 | N/A |
12/31/2016 | 5,101 | 407 | N/A | 311 | N/A |
9/30/2016 | 5,161 | 440 | N/A | 326 | N/A |
6/30/2016 | 5,227 | 448 | N/A | 378 | N/A |
3/31/2016 | 5,049 | 433 | N/A | 491 | N/A |
12/31/2015 | 4,916 | 421 | N/A | 477 | N/A |
9/30/2015 | 4,588 | 404 | N/A | 485 | N/A |
6/30/2015 | 4,456 | 367 | N/A | 391 | N/A |
3/31/2015 | 4,361 | 308 | N/A | 447 | N/A |
12/31/2014 | 4,316 | 289 | N/A | 404 | N/A |
9/30/2014 | 4,038 | 264 | N/A | 338 | N/A |
6/30/2014 | 3,860 | 258 | N/A | 467 | N/A |
3/31/2014 | 3,668 | 243 | N/A | 325 | N/A |
12/31/2013 | 3,584 | 232 | N/A | 242 | N/A |
9/30/2013 | 3,337 | 223 | N/A | 210 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 600422's forecast earnings growth (27.1% per year) is above the savings rate (2.9%).
Bénéfices vs marché: 600422's earnings (27.1% per year) are forecast to grow faster than the CN market (21.9% per year).
Croissance élevée des bénéfices: 600422's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: 600422's revenue (13.3% per year) is forecast to grow slower than the CN market (13.4% per year).
Croissance élevée des revenus: 600422's revenue (13.3% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 600422's Return on Equity is forecast to be low in 3 years time (12.3%).